International Journal of ISSN: 2470-9980IJVV

Vaccines & Vaccination
Letter to the Editor
Volume 2 Issue 2 - 2016
Vaccine Allied Biologics
Ibrahim MSAW Shnawa*
University of Qasim, Iraq
Received: March 30, 2016 | Published: April 07, 2016
*Corresponding author: Ibrahim MSAW Shnawa, College of Biotechnology, University of Qasim, Qasim, Babylon, Iraq, Email:
Citation: Shnawa IM (2016) Vaccine Allied Biologics. Int J Vaccines Vaccin 2(2): 00024. DOI: 10.15406/ijvv.2016.02.00024

Letter to Editor

One of the themes that are longly born in mind, those concerning “Vaccine versus Probiotics”. Then, if it is feasible to raise a question such as “Could we consider Probiotic as a vaccine, since they have an in-common indication, applications and/or attributes (Table 1). The common affairs are rather more than the different affairs. Thus, I think that they are forms of bio- therapeutics owning vaccine like potentials or one can say that they are vaccine-allied biologics.

Vaccines

Probiotics

Features

Pathogens or their subunits

Certain commensal bacteria

Starter

Specific in most cases

Nonspecific in most cases

Specificity

Stringent for human favor

Less stringent for human favor

Evaluation attitude

Needs special dispensing menu

Drug-like dispensing menu

Dispensing

Specific mostly

Nonspecific, mostly

Specificity

Immunoprphylaction

Biotherapy of various immune defects in man and animals

Indication

Massive use rather than individual cases

On individual basis more than massive

Use

Infectious, epidemic and pandemic threat or on travel to epidemic or endemic areas

Infectious and non-infectious

Disease nature

Based on affinity of B and T memory cells

Bacteriocin, immunomodulatory, anticancerous

Mode of action

Mild short duration like fever and ill

No appearent side effect

Side Effect

Due to vaccine or host born causes

Due to probiotic or host born causes

Failure

Table 1: Characteristics of vaccine versus probiotics.

References

  1. Banker DD (1980) Modren Practice In Immunization. Popular Prakshan, Bombay, India, pp. 384.
  2. Kaufmann SHE (2004) Novel Vaccination Strategies. Wiley-VCH, Germany, pp. 670.
  3. Kumar H, Salminen S, Vergagen H, Rowland I, Heimbach J, et al. (2015) Probiotics and prebiotics road to market. Curr Opin Biotech 32: 99-103.
  4. Quigley EMM (2016) Leaky gut-Concept or clinical entity. Curr Opin Gastroenterol 32(2): 74-79.
© 2014-2016 MedCrave Group, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use.
Creative Commons License Open Access by MedCrave Group is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at http://medcraveonline.com
Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version | Opera |Privacy Policy